Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2011



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs (B7)


Organizer(s) Nils Lonberg, Stephen M. Ansell and Edith Perez
February 6—11, 2011
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Oct 6, 2010
Late Abstract Deadline: Nov 8, 2010
Scholarship Deadline: Oct 6, 2010
Early Registration Deadline: Dec 6, 2010

Sponsored by Bristol-Myers Squibb Company, Novo Nordisk A/S and Takeda Pharmaceutical Company Limited

Summary of Meeting:
The therapeutic antibody field has matured to the point where antibody based therapies have become commonly prescribed for many diseases, particularly in cancer and rheumatology. This conference will bring together basic scientists, translational clinicians, and pharmaceutical industry scientists engaged in antibody drug discovery and development. Interactive discussions of current state of the art and areas for future work in this field will provide the structure for this meeting.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 6

15:00—19:30
Registration

Longs Peak Foyer
17:00
SuperBowl shown on the big screen with cash bar service available.

Longs/Grays Peak
18:15—19:15
Refreshments

Longs Peak Foyer
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
Mark X. Sliwkowski, Genentech, Inc., USA
Multiple Approaches to Targeting ErbB/HER Receptors in Solid Tumors


MONDAY, FEBRUARY 7

07:00—08:00
Breakfast

Quandary Peak
08:00—11:30
New Antibody Platform Technologies I: Fc Modifications, Bispecifics, and Fragments
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Paul W. H. I. Parren, Leiden University Medical Center, Netherlands

Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Bispecific Antibodies Designed for Polyclonal T Cell Engagement

Ian M. Tomlinson, GlaxoSmithKline, UK
Domain Antibodies for Human Therapy

Jeffrey V. Ravetch, Rockefeller University, USA
Hypersialylated Antibodies and Antibody Fragments for Immunomodulation

George J. Weiner, University of Iowa, USA
CDC and ADCC: Synergistic or Antagonistic Mechanisms?

Adrian Wiestner, NHLBI, National Institutes of Health, USA
Short Talk: Targeting the Fcmu-receptor: mAbs and Fc-Derived Protein Scaffolds Offer Complementary Approaches for Cancer Therapy

Philip D. Bardwell, AbbVie Bioresearch Center, USA
Short Talk: Re-Targeting Effector T Cells to Tumor Cell Targets using Dual Variable Domain-Immunoglobulins (DVD-IgTM)

Margaret Ellen Ackerman, Dartmouth College, USA
Short Talk: Tuning the Antibody Response: Natural Modulation of Antibody Glycosylation and Effector Function in HIV Infection

09:20—09:40
Coffee Break

Longs Peak Foyer
11:30—13:00
Poster Setup

Quandary Peak
13:00—22:00
Poster Viewing

Quandary Peak
11:30
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
New Antibody Platform Technologies II: Payloads
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Mark X. Sliwkowski, Genentech, Inc., USA

Nils Lonberg, Bristol-Myers Squibb, USA
Alkylating Agent Drug Conjugates

John M. Lambert, ImmunoGen, Inc., USA
Maytansinoids as Payloads for ADCs: Effective Drug Products for Treating Cancer

Peter D. Senter, Seattle Genetics Inc., USA
Empowered Antibodies for Cancer Therapy

Christoph Rader, The Scripps Research Institute, Scripps Florida, USA
Short Talk: A Sequential Program and Arm Strategy for Fc Fragments with a C-Terminal Selenocysteine

19:00—20:00
Social Hour with Lite Bites

Quandary Peak
19:30—22:00
Poster Session 1

Quandary Peak

TUESDAY, FEBRUARY 8

07:00—08:00
Breakfast

Quandary Peak
08:00—11:15
Immune Modulation I: Infectious Disease and Cancer
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia

Ian A. Wilson, The Scripps Research Institute, USA
Antibody Recognition of HIV-1 and Influenza

Don M. Benson, Ohio State University Comprehensive Cancer Center, USA
A Role for PD-1 in NK Cell Immunity Against Multiple Myeloma

James E. Crowe, Jr., Vanderbilt University Medical Center, USA
Naturally Occurring Human Antibody Responses to Viral Infections

Alan J. Korman, Bristol-Myers Squibb, USA
Lag-3 Targeted Immunotherapy

Gary J. Nabel, Sanofi, USA
Identification of Broadly Neutralizing Human MAbs to HIV-1: Applications to Vaccine Design, Passive Protection and HIV Therapy

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15—13:00
Poster Setup

Quandary Peak
13:00—22:00
Poster Viewing

Quandary Peak
11:15
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Immune Modulation II: Cancer
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Alan J. Korman, Bristol-Myers Squibb, USA

Kevin Heller, Bristol-Myers Squibb Company, USA
CTLA-4 Blockade for Cancer Immunotherapy

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
B7-H1/PD-1 Blockade for Cancer Immunotherapy

Paul M. Sondel, University of Wisconsin-Madison, USA
Cell-Mediated Destruction of Neuroblastoma and Melanoma Facilitated by Anti-GD2 Reagents ch14.18 and hu14.18-IL2

Andrew D. Weinberg, Earle A. Chiles Research Institute/Oregon Health & Science University, USA
Short Talk: Reshaping CD4 and CD8 Memory T Cell Proliferation by Treating Cancer Patients with an Anti-OX40 Ab: Immunologic and Clinical Assessment of a Phase I Trial

19:00—20:00
Social Hour with Lite Bites

Quandary Peak
19:30—22:00
Poster Session 2

Quandary Peak

WEDNESDAY, FEBRUARY 9

07:00—08:00
Breakfast

Quandary Peak
08:00—11:30
Immune Modulation III: Inflammatory Disease and Cancer
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Stephen M. Ansell, Mayo Clinic, USA

Trudi M. Veldman, AbbVie, USA
Modulation of the IL-1 Axis for RA and OA using DVD-IgTM Technology

Barbara White, Corbus Pharmaceuticals, USA
Blocking Type I Interferons in Systemic Lupus Erythematosus and Other Autoimmune Diseases

Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
Combination Chemo-Immunotherapy

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Checkpoint Blockade Combination Therapies

Eric Dobrzynski, GlaxoSmithKline, USA
Short Talk: PanELR: A High Affinity Neutralizing Monoclonal Antibody Targeting Multiple Human Pro-Inflammatory ELRCXC Chemokines

Stephen A. Beers, University of Southampton, UK
Short Talk: Re-Programming Macrophages to Enhance Antibody Immunotherapy

Joe Ponte, Tolerx, Inc., USA
Short Talk: In vitro and in vivo Characterization of TRX518, a Novel Anti-huGITR Monoclonal Antibody and New Phase 1 Clinical Trial Candidate

09:20—09:40
Coffee Break

Longs Peak Foyer
11:30
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Cancer I
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Ronald P. Taylor, University of Virginia School of Medicine, USA

Stephen M. Ansell, Mayo Clinic, USA
Therapeutic Antibody Combinations in the Treatment of Lymphoproliferative Disorders

Ronald Levy, Stanford University, USA
Combination Therapy to Enhance Antibody ADCC Activity: CD137 MAbs as an Activator of NK Cell Function

Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
CD38 as a Target for MM

Waleed Alduaij, University of Manchester, Paterson Institute of Cancer Research, UK
Short Talk: Novel Type II Anti-CD20 Monoclonal Antibody (GA101) Evokes Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Malignancies

19:00—20:00
Social Hour with Lite Bites

Quandary Peak

THURSDAY, FEBRUARY 10

07:00—08:00
Breakfast

Quandary Peak
08:00—11:15
Cancer II
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Nils Lonberg, Bristol-Myers Squibb, USA

Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands
Effective Functions of CD20 Antibodies

Georgiana K. Ellis, Seattle Cancer Care Alliance, USA
Cancer, Bone Health and Denosumab

Eric L. Sievers, Seattle Genetics, Inc., USA
Empowered Antibodies for Cancer Therapy: The Case of Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Wayne Chu, Genentech, Inc., USA
Trastuzumab-DM1 (T-DM1) Antibody-Drug Conjugate (ADC): Optimizing HER2-Targeted Cancer Therapy

Aaron K. Sato, Lake Pharma, USA
Short Talk: Wnt Pathway Inhibition Decreases Tumorigenicity and Promotes Differentiation of Human Tumors

Helle Jane Jacobsen, Symphogen A/S, Denmark
Short Talk: Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Cancer III
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Ronald Levy, Stanford University, USA

Ronald P. Taylor, University of Virginia School of Medicine, USA
Antigen Shaving as a Mechanism of Resistance to Antibody Therapy

Roy S. Herbst, University of Texas MD Anderson Cancer Center, USA
Antibodies Targeting Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor in Advanced Non-Small Cell Lung Cancer

John A. Latham, Alder BioPharmaceuticals, USA
Therapeutic Intervention in IL-6-Driven Disease: Clinical Experience with ALD518

Mark S. Cragg, University of Southampton, UK
Short Talk: Controlling Antigenic Modulation - Key Role of FcgammaRIIb in Regulating the Response to Rituximab

19:00—20:00
Social Hour with Lite Bites

Quandary Peak
20:00—23:00
Entertainment

Quandary Peak

FRIDAY, FEBRUARY 11

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Boehringer Ingelheim Pharmaceuticals, Inc. Bristol-Myers Squibb Company
Cephalon CovX Research LLC (Pfizer)
Novo Nordisk A/S Takeda Pharmaceutical Company Limited

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Abbott Laboratories


Alder Biopharmaceuticals, Inc.


Bristol-Myers Squibb Company


Genentech, Inc.


Genmab B.V.


ImmunoGen, Inc.


MedImmune


Micromet, Inc.


Seattle Genetics, Inc.


Genentech, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676